341 related articles for article (PubMed ID: 30140882)
41. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
[TBL] [Abstract][Full Text] [Related]
42. Very low human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests.
Zhao C; Elishaev E; Yuan KH; Yu J; Austin RM
Cancer; 2007 Oct; 111(5):292-7. PubMed ID: 17879368
[TBL] [Abstract][Full Text] [Related]
43. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
[TBL] [Abstract][Full Text] [Related]
44. Impact of COVID-19-related care disruptions on cervical cancer screening in the United States.
Burger EA; Jansen EE; Killen J; Kok IM; Smith MA; Sy S; Dunnewind N; G Campos N; Haas JS; Kobrin S; Kamineni A; Canfell K; Kim JJ
J Med Screen; 2021 Jun; 28(2):213-216. PubMed ID: 33730899
[TBL] [Abstract][Full Text] [Related]
45. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.
Kitchener HC; Almonte M; Gilham C; Dowie R; Stoykova B; Sargent A; Roberts C; Desai M; Peto J;
Health Technol Assess; 2009 Nov; 13(51):1-150, iii-iv. PubMed ID: 19891902
[TBL] [Abstract][Full Text] [Related]
46. Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years.
Jin XW; Lipold L; Foucher J; Sikon A; Brainard J; Belinson J; Schramm S; Nottingham K; Hu B; Rothberg MB
J Gen Intern Med; 2016 Nov; 31(11):1338-1344. PubMed ID: 27418345
[TBL] [Abstract][Full Text] [Related]
47. Evaluating the performance of three different cervical cancer screening modalities in a large prospective population-based cohort.
Song F; Du H; Xiao A; Wang C; Huang X; Liu Z; Zhao M; Men H; Wu R
J Infect Public Health; 2020 Nov; 13(11):1780-1786. PubMed ID: 32919932
[TBL] [Abstract][Full Text] [Related]
48. The ideal strategy for cervical cancer screening in Japan: Result from the Fukui Cervical Cancer Screening Study.
Kurokawa T; Onuma T; Shinagawa A; Chino Y; Kobayashi M; Yoshida Y
Cytopathology; 2018 Aug; 29(4):361-367. PubMed ID: 29768678
[TBL] [Abstract][Full Text] [Related]
49. Unindicated cervical cancer screening in adolescent females within a large healthcare system in the United States.
Hosier H; Sheth SS; Oliveira CR; Perley LE; Vash-Margita A
Am J Obstet Gynecol; 2021 Dec; 225(6):649.e1-649.e9. PubMed ID: 34256029
[TBL] [Abstract][Full Text] [Related]
50. Estimated US Cancer Deaths Prevented With Increased Use of Lung, Colorectal, Breast, and Cervical Cancer Screening.
Knudsen AB; Trentham-Dietz A; Kim JJ; Mandelblatt JS; Meza R; Zauber AG; Castle PE; Feuer EJ
JAMA Netw Open; 2023 Nov; 6(11):e2344698. PubMed ID: 37991759
[TBL] [Abstract][Full Text] [Related]
51. Assessment of US Preventive Services Task Force Guideline-Concordant Cervical Cancer Screening Rates and Reasons for Underscreening by Age, Race and Ethnicity, Sexual Orientation, Rurality, and Insurance, 2005 to 2019.
Suk R; Hong YR; Rajan SS; Xie Z; Zhu Y; Spencer JC
JAMA Netw Open; 2022 Jan; 5(1):e2143582. PubMed ID: 35040970
[TBL] [Abstract][Full Text] [Related]
52. Trends in the use of cervical cancer screening tests in a large medical claims database, United States, 2013-2019.
Qin J; Shahangian S; Saraiya M; Holt H; Gagnon M; Sawaya GF
Gynecol Oncol; 2021 Nov; 163(2):378-384. PubMed ID: 34507826
[TBL] [Abstract][Full Text] [Related]
53. Use Trends and Recent Expenditures for Cervical Cancer Screening-Associated Services in Medicare Fee-for-Service Beneficiaries Older Than 65 Years.
Qin J; Holt HK; Richards TB; Saraiya M; Sawaya GF
JAMA Intern Med; 2023 Jan; 183(1):11-20. PubMed ID: 36409511
[TBL] [Abstract][Full Text] [Related]
54. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.
Goldie SJ; Kuhn L; Denny L; Pollack A; Wright TC
JAMA; 2001 Jun; 285(24):3107-15. PubMed ID: 11427139
[TBL] [Abstract][Full Text] [Related]
55. Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States.
Cuzick J; Du R; Adcock R; Kinney W; Joste N; McDonald RM; English K; Torres SM; Saslow D; Wheeler CM;
Gynecol Oncol; 2021 Sep; 162(3):555-559. PubMed ID: 34253387
[TBL] [Abstract][Full Text] [Related]
56. Harms and benefits of cervical cancer screening among non-attenders in Switzerland: The transition towards HPV-based screening.
Catarino R; Vassilakos P; Petignat P; Combescure C
Prev Med Rep; 2022 Oct; 29():101929. PubMed ID: 35959498
[TBL] [Abstract][Full Text] [Related]
57. [Cost-effectiveness analysis of cervical cancer screening strategies in urban China].
Peng JR; Tao SY; Wen Y; Yang X; Ma JQ; Zhao F; Chen ZY; Zhang GT; Qiao YL; Zhao FH; Yang CX
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):154-160. PubMed ID: 30862148
[No Abstract] [Full Text] [Related]
58. Variation in cervical cancer screening test utilization and results in a United States-based program.
Dorismond VG; Saraiya M; Gopalani SV; Soman A; Kenney K; Miller J; Sawaya GF
Gynecol Oncol; 2024 May; 184():96-102. PubMed ID: 38301312
[TBL] [Abstract][Full Text] [Related]
59. Using Decision-Analytic Modeling to Isolate Interventions That Are Feasible, Efficient and Optimal: An Application from the Norwegian Cervical Cancer Screening Program.
Pedersen K; Sørbye SW; Burger EA; Lönnberg S; Kristiansen IS
Value Health; 2015 Dec; 18(8):1088-97. PubMed ID: 26686795
[TBL] [Abstract][Full Text] [Related]
60. Shift in harms and benefits of cervical cancer screening in the era of HPV screening and vaccination: a modelling study.
Kaljouw S; Jansen EEL; Aitken CA; de Kok IMCM
BJOG; 2022 Oct; 129(11):1862-1869. PubMed ID: 35429107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
